JPWO2020216847A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020216847A5
JPWO2020216847A5 JP2021562990A JP2021562990A JPWO2020216847A5 JP WO2020216847 A5 JPWO2020216847 A5 JP WO2020216847A5 JP 2021562990 A JP2021562990 A JP 2021562990A JP 2021562990 A JP2021562990 A JP 2021562990A JP WO2020216847 A5 JPWO2020216847 A5 JP WO2020216847A5
Authority
JP
Japan
Prior art keywords
antibody
sodium
sulfate
acetate
glutamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530050A5 (https=
JP2022530050A (ja
JP7671697B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061340 external-priority patent/WO2020216847A1/en
Publication of JP2022530050A publication Critical patent/JP2022530050A/ja
Publication of JP2022530050A5 publication Critical patent/JP2022530050A5/ja
Publication of JPWO2020216847A5 publication Critical patent/JPWO2020216847A5/ja
Priority to JP2025036010A priority Critical patent/JP2025087851A/ja
Application granted granted Critical
Publication of JP7671697B2 publication Critical patent/JP7671697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562990A 2019-04-23 2020-04-23 安定な低粘度抗体製剤およびその使用 Active JP7671697B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025036010A JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
EP20305145 2020-02-17
EP20305145.3 2020-02-17
PCT/EP2020/061340 WO2020216847A1 (en) 2019-04-23 2020-04-23 Stable, low-viscosity antibody formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036010A Division JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Publications (4)

Publication Number Publication Date
JP2022530050A JP2022530050A (ja) 2022-06-27
JP2022530050A5 JP2022530050A5 (https=) 2023-05-01
JPWO2020216847A5 true JPWO2020216847A5 (https=) 2023-05-01
JP7671697B2 JP7671697B2 (ja) 2025-05-02

Family

ID=70295163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562990A Active JP7671697B2 (ja) 2019-04-23 2020-04-23 安定な低粘度抗体製剤およびその使用
JP2025036010A Pending JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025036010A Pending JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Country Status (15)

Country Link
US (1) US20220218607A1 (https=)
EP (1) EP3958896A1 (https=)
JP (2) JP7671697B2 (https=)
KR (1) KR20220004104A (https=)
CN (1) CN114286690A (https=)
AU (1) AU2020262231A1 (https=)
BR (1) BR112021021099A2 (https=)
CA (1) CA3137464A1 (https=)
CO (1) CO2021015561A2 (https=)
IL (1) IL287435A (https=)
MA (1) MA55750A (https=)
MX (1) MX2021012968A (https=)
SG (1) SG11202111740PA (https=)
TW (1) TW202108171A (https=)
WO (1) WO2020216847A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022006882A (es) * 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP7080263B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤
US20260091081A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
US20220175663A1 (en) Stable liquid antibody formulation
CN102946858B (zh) 含有免疫球蛋白Fc的多肽的液体制剂
CA2672902A1 (en) Formulations
KR20160105535A (ko) TNF-α 항체의 약제학적 제형
EP3621652A1 (en) A conjugate of a tubulysin analog with branched linkers
RU2010121165A (ru) Составы паратиреоидного гормона и их применение
JP7671697B2 (ja) 安定な低粘度抗体製剤およびその使用
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
US20230414760A1 (en) Pharmaceutical formulation
CN116635077A (zh) Ceacam5抗体-药物缀合物制剂
RU2008121874A (ru) Стабильные фармацевтические составы, которые содержат интерфероны гамма и альфа в синергичных соотношениях
US11191778B2 (en) Multifunctional linker technology containing an N4 group
JPWO2020216847A5 (https=)
JP2004538275A5 (https=)
WO2022268214A1 (zh) Pcsk9抑制剂和glp-1受体激动剂的药物组合
RU2021133921A (ru) Стабильные маловязкие составы на основе антитела и пути их применения
JPS59216818A (ja) 経皮吸収外用製剤
US20210330801A1 (en) Novel protein drug conjugate formulation
RU2024111069A (ru) Лиофилизированные препараты полипептида enpp1 и их применение
RU2024127270A (ru) Препараты, содержащие биспецифическое антитело против claudin18.2/cd3, способ их получения и применение
RU2024101032A (ru) Составы на основе антитела к tgf-бета и их применение
TW202400233A (zh) 用於皮下投予之包含抗-her2抗體的藥學組合物
WO2022161554A4 (es) Composición farmacéutica que comprende el ghrp-6